FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Poma Eric E
2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2017
3. Issuer Name and Ticker or Trading Symbol
Molecular Templates, Inc. [MTEM]
(Last)
(First)
(Middle)
C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD., SUITE 100
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

AUSTIN, TX 78729
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1)   (2) 02/23/2019 Common Stock 152,945 $ 0.42 D  
Stock Option (right to buy) (1)   (3) 07/12/2021 Common Stock 90,514 $ 0.71 D  
Stock Option (right to buy) (1)   (4) 07/10/2022 Common Stock 34,156 $ 0.71 D  
Stock Option (right to buy) (1)   (5) 11/19/2024 Common Stock 220,560 $ 1.27 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Poma Eric E
C/O MOLECULAR TEMPLATES, INC.
9301 AMBERGLEN BLVD., SUITE 100
AUSTIN, TX 78729
      See Remarks  

Signatures

/s/ Jason S. Kim, attorney-in-fact 08/11/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Shares of common stock of the corporation then known as Molecular Templates, Inc. ("Old Molecular") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of March 16, 2017, by and among the Issuer, Trojan Merger Sub, Inc. and Old Molecular (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was exchanged for 7.7844 shares of the Issuer's common stock, which then underwent a reverse split of 11-to-1.
(2) On February 23, 2009, Reporting Person was granted an option to purchase 216,125 shares of common stock of Old Molecular under the 2009 Stock Plan (the "Plan") at an exercise price of $0.30 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 152,945 shares of the Issuer's common stock at a per share exercise price of $0.42. One fifth of the total number of shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, which is February 23, 2009 and, thereafter, one sixtieth of the total number of Shares subject to the Option shall vest on the corresponding day of each month after such first anniversary, provided that at the relevant vesting dates the Reporting Person continues service to the Issuer and has not been terminated as defined in and as determined under the Plan. The option expires ten years after the date of the grant.
(3) On July 12, 2011, Reporting Person was granted an option to purchase 127,904 shares of common stock of Old Molecular under the 2009 Stock Plan (the "Plan") at an exercise price of $0.50 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 90,514 shares of the Issuer's common stock at a per share exercise price of $0.71. The shares subject to the option shall vest in 60 equal monthly installments beginning on the Vesting Commencement Date, which is July 12, 2011, provided that at the relevant vesting dates the Reporting Person continues service to the Issuer and has not been terminated as defined in and as determined under the Plan. The option expires ten years after the date of the grant.
(4) On July 10, 2012, Reporting Person was granted an option to purchase 48,266 shares of common stock of Old Molecular under the 2009 Stock Plan (the "Plan") at an exercise price of $0.50 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 34,156 shares of the Issuer's common stock at a per share exercise price of $0.71. The shares subject to the option shall vest in 60 equal monthly installments beginning on the Vesting Commencement Date, which is December 5, 2011, provided that at the relevant vesting dates the Reporting Person continues service to the Issuer and has not been terminated as defined in and as determined under the Plan. The option expires ten years after the date of the grant.
(5) On November 19, 2014, Reporting Person was granted an option to purchase 311,670 shares of common stock of Old Molecular under the 2009 Stock Plan (the "Plan") at an exercise price of $0.90 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 220,560 shares of the Issuer's common stock at a per share exercise price of $1.27. One fourth of the total number of shares subject to the option shall vest on the one year anniversary of the Vesting Commencement Date, which is September 19, 2013 and, thereafter, the remaining shares shall vest in 36 equal monthly installments, provided that at the relevant vesting dates the Reporting Person continues service to the Issuer and has not been terminated as defined in and as determined under the Plan. The option expires ten years after the date of the grant.
 
Remarks:
Exhibit 24.1 - Power of Attorney

Chief Executive Officer and Chief Scientific Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.